Kite Pharma
YESCARTA
Manufacturer:
Kite Pharma
Name:
YESCARTA
HCPCS Code Descriptor:
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Category:
Q Code
HCPCS:
Q2041
NDC(s):
71287-0119-01
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
YESCARTA is an Oncology drug manufactured by Kite Pharma and administered via the Intravenous route of administration. The Q Code: Q2041 is aligned to the drug YESCARTA.